Skip to main content
SpringerLink
Log in

Safety of Inhaled Budesonide

Clinical Manifestations of Systemic Corticosteroid-Related Adverse Effects

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Inhaled corticosteroid (ICS) therapy is central to the long-term management of asthma and is extensively used in the management of chronic obstructive pulmonary disease (COPD). While administration via inhalation limits systemic exposure compared with oral or injected corticosteroids and, therefore, the risk of systemic corticosteroid-related adverse effects, concerns over the long-term safety of ICS persist. The assessment of the long-term effects of ICS therapy requires considerable research effort over years or even decades. Surrogate markers/predictors for clinical endpoints such as adrenal crisis, reduced final height and fractures have been identified for use in relatively short-term studies. However, the predictive value of such markers remains questionable.

Inhaled budesonide has been available since the early 1980s and there is a considerable evidence base investigating the safety of this agent. To assess the long-term safety of inhaled budesonide therapy in terms of the actual incidence of the clinical endpoints adrenal crisis/insufficiency, reduced final height, fractures and pregnancy complications, we undertook a review of the scientific literature. The external databases BIOSIS, Cochrane Central Register of Controlled Trials, Current Contents, EMBASE, International Pharmaceutical Abstracts and MED-LINE were searched, in addition to AstraZeneca's internal product literature database Planet, up to 29 February 2008. Only original articles of epidemiological studies, national surveys, clinical trials and case reports concerning inhaled budesonide were included.

Eight surveys of adrenal crisis were found. The only survey with specified criteria for diagnosis involved 2912 paediatricians and endocrinologists and revealed 33 patients with adrenal crisis associated with ICS therapy; only one patient used budesonide (in co-treatment with fluticasone propionate). In addition, 14 case reports of adrenal crisis in budesonide-treated patients were found. In only two of these, budesonide was used at recommended doses and in the absence of interacting medication.

Three retrospective studies and one prospective study assessing final height were found. None of them showed any reduced final height in patients receiving inhaled budesonide during childhood or adolescence.

Seventeen epidemiological studies investigating the risk of fractures were found. When adjusting for confounding factors, they did not provide any unequivocal data for an increased fracture risk with budesonide. Four prospective placebo-controlled clinical trials of 2–6 years duration with inhaled budesonide in patients with asthma or COPD were found. None of the studies identified any association between inhaled budesonide and increased risk for fractures.

Four studies using data from the Swedish birth and health registries showed there was no increased risk for congenital malformations, cardiovascular defects, decreased gestational age, birth weight or birth length among infants born to women using inhaled budesonide during pregnancy compared with the general population. This was confirmed by five observational studies in Australia, Canada, Hungary, Japan and the US. Similarly, one randomized clinical trial comparing pregnancy outcomes among asthma patients receiving inhaled budesonide or placebo did not demonstrate any difference in outcome of pregnancy.

In summary, based on 25 years of experience with different doses and in different populations, inhaled budesonide therapy only in very rare cases appears to be associated with an increased risk of adrenal crisis, reduction in final height, increases in the number of fractures or complications during pregnancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Fig. 2
Table III
Fig. 3

Similar content being viewed by others

References

  1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2006 [online]. Available from URL: http://www.ginasthma.org [Accessed 2007 Jan 17]

  2. National Heart Lung and Blood Institute National Asthma Education Program Expert Panel report. Guidelines for the diagnosis and management of asthma. J Allergy Clin Immunol 1991; 88 (3 Pt 2): 425–534

    Article  Google Scholar 

  3. International Asthma Management Project. International consensus report on diagnosis and management of asthma. Allergy 1992; 47 (13 Suppl.): 1–61

    Article  Google Scholar 

  4. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159(9): 941–55

    Article  PubMed  CAS  Google Scholar 

  5. Pedersen S. Do inhaled corticosteroids inhibit growth in children? Am J Respir Crit Care Med 2001; 164(4): 521–35

    PubMed  CAS  Google Scholar 

  6. Price J, Hindmarsh P, Hughes S, et al. Evaluating the effects of asthma therapy on childhood growth: what can be learnt from the published literature? Eur Respir J 2002; 19(6): 1179–93

    Article  PubMed  CAS  Google Scholar 

  7. Fuller R, Johnson M, Buye A. Fluticasone propionate: an update on preclinical and clinical experience. Respir Med 1995; 89 Suppl. A: 3–18

    Article  PubMed  Google Scholar 

  8. Todd GRG, Acerini CL, Ross-Russell R, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87(6): 457–61

    Article  PubMed  CAS  Google Scholar 

  9. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354(19): 1985–97

    Article  PubMed  CAS  Google Scholar 

  10. Visser MJ, van der Veer E, Postma DS, et al. Side-effects of fluticasone in asthmatic children: no effects after dose reduction. Eur Respir J 2004; 24(3): 420–5

    Article  PubMed  CAS  Google Scholar 

  11. Kelly HW. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003; 112(3): 469–78

    Article  PubMed  CAS  Google Scholar 

  12. O'Connell EJ. Review of the unique properties of budesonide. Clin Ther 2003; 25 Suppl. C: C42–60

    Article  PubMed  Google Scholar 

  13. Thorsson L, Edsbäcker S, Källén A, et al. Pharmacokinetics and systemic activity of fluticasone via Diskus(R) and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001; 52(5): 529–38

    Article  PubMed  CAS  Google Scholar 

  14. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 112 (3 Suppl.): S1–S40

    Article  PubMed  CAS  Google Scholar 

  15. Molimard M, Pollet C, Girodet P, et al. Adrenal insufficiencies associated with inhaled corticosteroids: an under recognised event? [abstract no. 48]. Fundam Clin Pharmacol 2007; 21 Suppl. 1: 10

    Google Scholar 

  16. Daveluy A, Pollet C, Girodet P, et al. Adrenal insufficiency with inhaled corticosteroids: an under-recognised event? [abstract]. Drug Saf 2007; 30(10): 24

    Google Scholar 

  17. Barton K. Fluticasone and adrenal suppression. Canadian Adverse Reaction Newsletter 2003; 13(4): 2

    Google Scholar 

  18. Adverse Drug Reactions Advisory Committee (ADRAC). Fluticasone and adrenal crisis. Australian Adverse Drug Reactions Bulletin 2003; 22(2): 6

    Google Scholar 

  19. Mjörndal T, Danell Boman M, Hagg S, et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 2002; 11(1): 65–72

    Article  PubMed  Google Scholar 

  20. Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002; 87(6): 462–6

    Article  PubMed  CAS  Google Scholar 

  21. de Vries TW, de Langen-Wouterse JJ, van Puijenbroek E, et al. Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. Eur J Clin Pharmacol 2006; 62(5): 343–6

    Article  PubMed  CAS  Google Scholar 

  22. Mortimer KJ, Tata LJ, Smith CJ, et al. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006; 61(5): 405–8

    Article  PubMed  CAS  Google Scholar 

  23. Zwaan CM, Odink RJ, Delemarre-van de Waal HA, et al. Acute adrenal insufficiency after discontinuation of inhaled corticosteroid therapy. Lancet 1992; 340: 1289–90

    Article  PubMed  CAS  Google Scholar 

  24. Kajantie E, Otonkoski T, Kivirikko S, et al. A syndrome with multiple malformations, mental retardation, and ACTH deficiency. Am J Med Genet 2004; 126A(3): 313–8

    Article  PubMed  Google Scholar 

  25. Dunlop KA, Carson DJ, Shields MD. Hypoglycemia due to adrenal suppression secondary to high-dose nebulized corticosteroid. Pediatr Pulmonol 2002; 34(1): 85–6

    Article  PubMed  CAS  Google Scholar 

  26. Wong J, Black P. Acute adrenal insufficiency associated with high dose inhaled steroids [letter]. BMJ 1992; 304(6839): 1415

    Article  PubMed  CAS  Google Scholar 

  27. Main KM, Skov M, Sillesen IB, et al. Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient. Acta Paediatr 2002; 91(9): 1008–11

    Article  PubMed  CAS  Google Scholar 

  28. Bolland MJ, Bagg W, Thomas MG, et al. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 2004; 38(1): 46–9

    Article  PubMed  Google Scholar 

  29. Samaras K, Pett S, Gowers A, et al. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90(7): 4394–8

    Article  PubMed  CAS  Google Scholar 

  30. Rask E, Eriksson JW, Forsberg G. Case reports of inhaled corticosteroid-induced adrenal suppression [in Swedish]. Läkartidningen 1997; 94(40): 3529–30, 3533

    PubMed  CAS  Google Scholar 

  31. Patel L, Wales JK, Kibirige MS, et al. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch Dis Child 2001; 85(4): 330–4

    Article  PubMed  CAS  Google Scholar 

  32. Todd GRG, Acerini CL, Buck JJ, et al. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Eur Respir J 2002; 19(6): 1207–9

    Article  PubMed  CAS  Google Scholar 

  33. Macdessi JS, Randell TL, Donaghue KC, et al. Adrenal crises in children treated with high-dose inhaled corticosteroids for asthma. Med J Aust 2003; 178(5): 214–6

    PubMed  Google Scholar 

  34. Todd GRG, Wright D, Ryan M. Acute adrenal insufficiency in a patient with asthma after changing from fluticasone propionate to budesonide. J Allergy Clin Immunol 1999; 103(5): 956–7

    Article  PubMed  CAS  Google Scholar 

  35. De Swert LF, Wouters C, de Zegher F. Myopathy in children receiving high-dose inhaled fluticasone. N Engl J Med 2004; 350(11): 1157–9

    Article  PubMed  Google Scholar 

  36. Baumgartner-Bonnevay C, Derharoutunian C, Daumont M, et al. Diabetes mellitus and adrenocortical insufficiency possibly associated with high-dose inhaled budesonide [in French]. Pharm Hosp 2000; 35(143): 27–33

    Google Scholar 

  37. van Heest JA, Bokma JA, Van Oudheusden LJ, et al. Adrenocortical suppression attributed to budesonide [in Dutch]. Ned Tijdschr Geneeskd 1994; 138: 2204–7

    PubMed  Google Scholar 

  38. De Wachter E, Vanbesien J, De Schutter I, et al. Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide. Eur J Pediatr 2003; 162(7-8): 488–9

    Article  PubMed  Google Scholar 

  39. De Wachter E, Malfroot A, De Schutter I, et al. Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibros 2003; 2(2): 72–5

    Article  PubMed  CAS  Google Scholar 

  40. Jørgensen IM, Johansen HK, Frederiksen B, et al. Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr Pulmonol 2003; 36(5): 439–46

    Article  PubMed  Google Scholar 

  41. Zimmerman B, Gold M, Wherrett D, et al. Adrenal suppression in two patients with asthma treated with low doses of the inhaled steroid fluticasone propionate. J Allergy Clin Immunol 1998; 101(3): 425–6

    Article  PubMed  CAS  Google Scholar 

  42. Bardelas JA, Krege JH. Case report: Addison's disease from inhaled fluticasone 880μg/day [abstract no. 728]. J Allergy Clin Immunol 2002; 109 (1 Suppl. S): S240

    Article  Google Scholar 

  43. Todd G, Dunlop K, McNaboe J, et al. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996; 348(9019): 27–9

    Article  PubMed  CAS  Google Scholar 

  44. Wilson AM, Blumsohn A, Jung RT, et al. Asthma and Cushing's syndrome. Chest 2000; 117(2): 593–4

    Article  PubMed  CAS  Google Scholar 

  45. Molis WE, Hartz MF. Prolonged adrenal suppression during inhaled fluticasone and intranasal triamcinolone therapy [abstract no. P3]. Ann Allergy Asthma Immunol 2007; 98 (1 Suppl. 1): A35

    Google Scholar 

  46. Norjavaara E, Gerhardsson de Verdier M, Lindmark B. Reduced height in Swedish men with asthma at the age of conscription for military service. J Pediatr 2000; 137(1): 25–9

    Article  PubMed  CAS  Google Scholar 

  47. Larsson L, Gerhardsson de Verdier M, Lindmark B, et al. Budesonide-treated asthmatic adolescents attain target height: a population-based follow-up study from Sweden. Pharmacoepidemiol Drug Saf 2002; 11(8): 715–20

    Article  PubMed  CAS  Google Scholar 

  48. Van Bever HP, Desager KN, Lijssens N, et al. Does treatment of asthmatic children with inhaled corticosteroids affect their adult height? Pediatr Pulmonol 1999; 27(6): 369–75

    Article  PubMed  Google Scholar 

  49. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343(15): 1064–9

    Article  PubMed  CAS  Google Scholar 

  50. Agertoft L, Pedersen S. Adult height in children treated with inhaled budesonide is normal but reached late [abstract no. P4080]. Eur Respir J 2006; 28 Suppl. 50: 709s

    Google Scholar 

  51. Agertoft L, Pedersen S. Adult height in children with asthma treated with inhaled budesonide is normal but reached at a later age than in healthy children [abstract]. Endocr Soc Annu Meet 2007; 457: P2–507

    Google Scholar 

  52. Adachi J. Corticosteroid-induced osteoporosis. Int J Fertil Womens Med 2001; 46(4): 190–205

    PubMed  CAS  Google Scholar 

  53. Lalloo UG, Malolepszy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003; 123(5): 1480–7

    Article  PubMed  CAS  Google Scholar 

  54. Leflein JG, Baker JW, Eigen H, et al. Safety features of budesonide inhalation suspension in the long-term treatment of asthma in young children. Adv Ther 2005; 22(3): 198–207

    Article  PubMed  CAS  Google Scholar 

  55. Pohunek P, Kuna P, Jorup C, et al. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatr Allergy Immunol 2006; 17(6): 458–65

    Article  PubMed  Google Scholar 

  56. Möller C, Strömberg L, Oldaeus G, et al. Efficacy of once-daily versus twice-daily administration of budesonide by Turbuhaler in children with stable asthma. Pediatr Pulmonol 1999; 28(5): 337–43

    Article  PubMed  Google Scholar 

  57. Bisgaard H, Le Roux P, Bjamer D, et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006; 130(6): 1733–43

    Article  PubMed  CAS  Google Scholar 

  58. Davis KJ, Clark D, Knobil K. Inhaled corticosteroid use and risk of non-vertebral fracture among adults with chronic obstructive lung disease in UK general practice [abstract]. Chest 2003; 124 (4 Suppl. S): 166S

    Google Scholar 

  59. van Staa TP, Leufkens HGM, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16(3): 581–8

    Article  PubMed  Google Scholar 

  60. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med 2005; 257(4): 374–84

    Article  PubMed  CAS  Google Scholar 

  61. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest 2007; 132(5): 1599–607

    Article  PubMed  CAS  Google Scholar 

  62. Hubbard RB, Smith CJP, Smeeth L, et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002; 166(12): 1563–6

    Article  PubMed  Google Scholar 

  63. Vestergaard P, Olsen ML, Johnsen SP, et al. Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med 2003; 254(5): 486–93

    Article  PubMed  CAS  Google Scholar 

  64. de Vries F, Pouwels S, Lammers JWJ, et al. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 2007; 261(2): 170–7

    PubMed  Google Scholar 

  65. de Vries F, van Staa TP, Bracke M, et al. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J 2005; 25(5): 879–84

    Article  PubMed  Google Scholar 

  66. Schlienger RG, Jick SS, Meier CR. Inhaled corticosteroids and the risk of fractures in children and adolescents. Pediatrics 2004; 114(2): 469–73

    Article  PubMed  Google Scholar 

  67. Johannes CB, Schneider GA, Dube TJ, et al. The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. Chest 2005; 127(1): 89–97

    Article  PubMed  CAS  Google Scholar 

  68. Pujades-Rodríguez M, Smith CJP, Hubbard RB. Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease. Q J Med 2007; 100(8): 509–17

    Article  Google Scholar 

  69. Suissa S, Baltzan M, Kremer R, et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004; 169(1): 83–8

    Article  PubMed  Google Scholar 

  70. van Staa TP, Bishop N, Leufkens HGM, et al. Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos Int 2004; 15(10): 785–91

    Article  PubMed  CAS  Google Scholar 

  71. Hubbard R, Tattersfield A, Smith C, et al. Use of inhaled corticosteroids and the risk of fracture. Chest 2006; 130(4): 1082–8

    Article  PubMed  CAS  Google Scholar 

  72. Lau E, Mamdani M, Tu K. Inhaled or systemic corticosteroids and the risk of hospitalization for hip fracture among elderly women. Am J Med 2003; 114(2): 142–5

    Article  PubMed  CAS  Google Scholar 

  73. Walsh LJ, Lewis SA, Wong CA, et al. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med 2002; 166(5): 691–5

    Article  PubMed  Google Scholar 

  74. Ferencz V, Meszaros S, Csupor E, et al. Increased bone fracture prevalence in postmenopausal women suffering from pollenallergy. Osteoporos Int 2006; 17(3): 484–91

    Article  PubMed  Google Scholar 

  75. Tattersfield AE, Town GI, Johnell O, et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax 2001; 56(4): 272–8

    Article  PubMed  CAS  Google Scholar 

  76. Johnell O, Pauwels R, Lofdahl CG, et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler®. Eur Respir J 2002; 19(6): 1058–63

    Article  PubMed  CAS  Google Scholar 

  77. Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340(25): 1948–53

    Article  PubMed  CAS  Google Scholar 

  78. Pedersen S, O'Byrne PM, Busse WW, et al. Fracture rate in patients with asthma receiving long-term early intervention with budesonide: the START study [abstract no. P1855]. Eur Respir J 2005; 26 Suppl. 49: 276s

    Google Scholar 

  79. Sheffer AL, Silverman M, Woolcock AJ, et al. Long-term safety of once-daily budesonide in patients with early-onset mild persistent asthma: results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study. Ann Allergy Asthma Immunol 2005; 94(1): 48–54

    Article  PubMed  CAS  Google Scholar 

  80. Silverman M, Sheffer AL, Diaz PV, et al. Safety and tolerability of inhaled budesonide in children in the Steroid Treatment As Regular Therapy in early asthma (START) trial. Pediatr Allergy Immunol 2006; 17 Suppl. 17: 14–20

    Article  PubMed  Google Scholar 

  81. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343(15): 1054–63

    Article  Google Scholar 

  82. Murphy VE, Gibson P, Talbot PL, et al. Severe asthma exacerbations during pregnancy. Obstet Gynecol 2005; 106 (5 Pt 1): 1046–54

    Article  PubMed  Google Scholar 

  83. Otsuka H, Narushima M, Suzuki H. Assessment of inhaled corticosteroid therapy for asthma treatment during pregnancy. Allergol Int 2005; 54(3): 381–6

    Article  CAS  Google Scholar 

  84. Wen SW, Demissie K, Liu S. Adverse outcomes in pregnancies of asthmatic women: results from a Canadian population. Ann Epidemiol 2001; 11(1): 7–12

    Article  PubMed  CAS  Google Scholar 

  85. Sorensen TK, Dempsey JC, Xiao R, et al. Maternal asthma and risk of preterm delivery. Ann Epidemiol 2003; 13(4): 267–72

    Article  PubMed  Google Scholar 

  86. Kelly YJ, Brabin BJ, Milligan P, et al. Maternal asthma, premature birth, and the risk of respiratory morbidity in schoolchildren in Merseyside. Thorax 1995; 50(5): 525–30

    Article  PubMed  CAS  Google Scholar 

  87. Källén B, Rydhstroem H, Åberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999; 93(3): 392–5

    Article  PubMed  Google Scholar 

  88. Källén BAJ, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003; 17(3): 255–61

    Article  PubMed  CAS  Google Scholar 

  89. Norjavaara E, Gerhardsson de Verdier M. Normal pregnancy outcomes in a population-based study including 2968 pregnant women exposed to budesonide. J Allergy Clin Immunol 2003; 111(4): 736–42

    Article  PubMed  CAS  Google Scholar 

  90. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy: 3. Congenital malformations in the infants. Eur J Clin Pharmacol 2007; 63(4): 383–8

    Google Scholar 

  91. Blais L, Beauchesne M-F, Rey E, et al. Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. Thorax 2007; 62(4): 320–8

    Article  PubMed  Google Scholar 

  92. Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197(6): 585. e1-7

    Article  PubMed  CAS  Google Scholar 

  93. Tamasi L, Somoskovi A, Muller V, et al. A population-based case-control study on the effect of bronchial asthma during pregnancy for congenital abnormalities of the offspring. J Asthma 2006; 43(1): 81–6

    Article  PubMed  Google Scholar 

  94. Namazy J, Schatz M, Long L, et al. Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth. J Allergy Clin Immunol 2004; 113(3): 427–32

    Article  PubMed  CAS  Google Scholar 

  95. Bakhireva LN, Jones KL, Schatz M, et al. Asthma medication use in pregnancy and fetal growth. J Allergy Clin Immunol 2005; 116(3): 503–9

    Article  PubMed  CAS  Google Scholar 

  96. Murphy VE, Gibson PG, Giles WB, et al. Maternal asthma is associated with reduced female fetal growth. Am J Respir Crit Care Med 2003; 168(11): 1317–23

    Article  PubMed  Google Scholar 

  97. Murphy VE, Smith R, Giles WB, et al. Reduced 11beta-hydroxysteroid dehydrogenase type 2 activity is associated with decreased birth weight centile in pregnancies complicated by asthma. J Clin Endocrinol Metab 2002; 87(4): 1660–8

    Article  PubMed  CAS  Google Scholar 

  98. Clifton VL, Rennie N, Murphy VE. Effect of inhaled glucocorticoid treatment on placental 11beta-hydroxysteroid dehydrogenase type 2 activity and neonatal birthweight in pregnancies complicated by asthma. Aust N Z J Obstet Gynaecol 2006; 46(2): 136–40

    Article  PubMed  Google Scholar 

  99. Silverman M, Sheffer A, Diaz PV, et al. Outcome of pregnancy in a randomized controlled study of patients with asthma exposed to budesonide. Ann Allergy Asthma Immunol 2005; 95(6): 566–70

    Article  PubMed  Google Scholar 

  100. Hagwall N, Engström E, Hellström A, et al. Periventricular leukomalacia and retinopathy in a term infant born to a mother with asthma. Dev Med Child Neurol 2006; 48(4): 301–3

    Article  PubMed  Google Scholar 

  101. Johnsson E, Larsson G, Ljunggren M. Severe malformations in infant born to hyperthyroid woman on methimazole [letter]. Lancet 1997; 350(9090): 1520

    Article  PubMed  CAS  Google Scholar 

  102. DeRenzo JS, Vallejo MC, Ramanathan S. Failed regional anesthesia with reduced spinal bupivacaine dosage in a parturient with achondroplasia presenting for urgent cesarean section. Int J Obstet Anesth 2005; 14(2): 175–8

    Article  Google Scholar 

  103. Nørgård B, Pedersen L, Jacobsen J, et al. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 2004; 19(6): 679–85

    Article  PubMed  CAS  Google Scholar 

  104. Allen DB. Influence of inhaled corticosteroids on growth: a pediatric endocrinologist's perspective. Acta Paediatr 1998; (2): 123–9

    Article  Google Scholar 

  105. Derendorf H. Corticosteroid pharmacokinetic/pharmacodynamic parameters and their relationship to safety and efficacy. Allergy Asthma Proc 2005; 26(5): 327–35

    PubMed  CAS  Google Scholar 

  106. Edsbäcker S, Johansson CJ. Airway selectivity: an update of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids. Basic Clin Pharmacol Toxicol 2006; 98(6): 523–36

    Article  PubMed  Google Scholar 

  107. Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther 2003; 25 Suppl. 3: C28–41

    Article  PubMed  CAS  Google Scholar 

  108. Borgström L, Bengtsson T, Derom E, et al. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler®. Int J Pharm 2000; 193(2): 227–30

    Article  PubMed  Google Scholar 

  109. Aronson J. Corticosteroids: glucocorticoids. In: Meyler's side effect of drugs: the international encyclopedia of adverse drug reactions and interactions. 15th ed. Oxford: Elsevier, 2006: 906–58

    Google Scholar 

  110. Duh MS, Walker AM, Lindmark B, et al. Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. Ann Allergy Asthma Immunol 2000; 85(5): 356–61

    Article  PubMed  CAS  Google Scholar 

  111. Agertoft L, Larsen FE, Pedersen S. Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J 1998; 12(1): 130–5

    Article  PubMed  CAS  Google Scholar 

  112. Turpeinen M, Kari O, HEICA study group. Posterior subcapsular opacities not observed in children treated for 18 months with budesonide Turbuhaler® [abstract no. P1936]. Eur Respir J 2001; 18 Suppl. 33: 290s

    Google Scholar 

  113. British Thoracic Society. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52 Suppl. 1: S1–20

    Article  Google Scholar 

  114. de Vries F, Pouwels S, Bracke M, et al. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 2006; 16(6): 612–9

    Article  CAS  Google Scholar 

  115. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128(4): 2099–107

    Article  PubMed  Google Scholar 

  116. Jørgensen NR, Schwarz P, Holme I, et al. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 2007; 101(1): 177–85

    Article  PubMed  Google Scholar 

  117. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170(12): 1286–93

    Article  PubMed  Google Scholar 

  118. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(12): 1259–65

    Article  PubMed  Google Scholar 

  119. Callaghan ML. Position statement: the use of newer asthma and allergy medications during pregnancy. Ann Allergy Asthma Immunol 2000; 84(5): 475–80

    Article  Google Scholar 

  120. NAEPP Expert Panel Report. Managing asthma during pregnancy: recommendations for pharmacologic treatment. 2004 update. J Allergy Clin Immunol 2005; 115(1): 34–46

    Article  Google Scholar 

  121. Gluck PA, Gluck JC. A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide. Curr Med Res Opin 2005; 21(7): 1075–84

    Article  PubMed  CAS  Google Scholar 

  122. Fält A, Bengtsson T, Kennedy B-M, et al. Exposure of infants to budesonide through breast milk of asthmatic mothers. J Allergy Clin Immunol 2007; 120(4): 798–802

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors are all full-time employees of and own stock in AstraZeneca R&D, Lund, Sweden. The authors would like to thank Jarl Ingelf (AstraZeneca) for his guidance and review of this article, and Ian Wright (Wright Medical Communications Ltd) who provided editorial assistance on behalf of AstraZeneca.

Author information

Authors and Affiliations

  1. Patient Safety, Clinical Development, AstraZeneca R&D Lund, 221 87, Lund, Sweden

    Camilla Christensson, Anders Thorén &  Bengt Lindberg

  2. Department of Pediatrics, Malmö University Hospital, Malmö, Sweden

    Bengt Lindberg

Authors
  1. Camilla Christensson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anders Thorén
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bengt Lindberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Christensson, C., Thorén, A. & Lindberg, B. Safety of Inhaled Budesonide. Drug-Safety 31, 965–988 (2008). https://doi.org/10.2165/00002018-200831110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831110-00002

Keywords

Search

Navigation